Laurus Labs Q2 FY26 – Strong Turnaround with Sharp Profit Surge

Laurus Labs delivered a stellar Q2 FY26 performance, marked by strong recovery in profitability and robust sales growth, supported by improved margins in its CDMO and formulation businesses. • Sales: ↑ 35% YoY to ₹1,653 crore (vs ₹1,224 crore in Sep 2024) • EBIDT: ↑ 126% YoY to ₹403 crore (vs ₹178 crore) • Net Profit: ↑ 883% YoY to ₹194 crore (vs ₹20 crore) • EPS: ↑ 876% YoY to ₹3.61 (vs ₹0.37) At a price of ₹934, market cap ₹50,441 crore, and PE 73.8, Laurus Labs showcased a strong earnings rebound, signalling a turnaround phase driven by operational efficiency and higher-margin business contributions.